Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2021 | 1 |
2024 | 1 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
[Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study].
Zhonghua Gan Zang Bing Za Zhi. 2021 Apr 20;29(4):326-331. doi: 10.3760/cma.j.cn501113-20210329-00148.
Zhonghua Gan Zang Bing Za Zhi. 2021.
PMID: 33979958
Chinese.
Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study.
Yuan G, Li W, Zang M, Li R, Li Q, Hu X, Zhang Q, Huang W, Ruan J, Pang H, Chen J.
Yuan G, et al.
Discov Oncol. 2024 Mar 9;15(1):68. doi: 10.1007/s12672-024-00917-1.
Discov Oncol. 2024.
PMID: 38460053
Free PMC article.
Item in Clipboard
Cite
Cite